Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefuroxime + clavulanate is an oral fixed-dose combination antibiotic consisting of cefuroxime axetil, a second-generation cephalosporin, and potassium clavulanate, a beta-lactamase inhibitor. Cefuroxime works by binding to penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis, leading to cell lysis. Clavulanate acts as a suicide inhibitor of beta-lactamase enzymes, preventing the enzymatic degradation of cefuroxime and restoring its activity against beta-lactamase-producing bacterial strains. This combination is widely used in countries like India for the treatment of various mild-to-moderate bacterial infections, including respiratory tract infections (bronchitis, pneumonia, sinusitis, tonsillitis), urinary tract infections, skin and soft tissue infections, and gonococcal urethritis. It is not approved by the US FDA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefuroxime + clavulanate.